U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Inactive Ingredients in Approved Drug Products Search

Inactive Ingredient Search for Approved Drug Products

You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with C

Quarter Inactive Ingredient Route of Administration Dosage Form Maximum Potency per unit dose Maximum Daily Exposure Status
138005 Q2 2022 CROSPOVIDONE ORAL TABLET, DELAYED RELEASE 280mg Correction
138006 Q3 2022 CROSPOVIDONE ORAL TABLET, DELAYED RELEASE 224mg Correction
138089 Q3 2022 CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) ORAL TABLET, EXTENDED RELEASE 175.00 mg 525mg Deletion
138091 Q3 2022 CITRIC ACID MONOHYDRATE NASAL AEROSOL, SPRAY 3.50 mg Deletion
138092 Q3 2022 COTTONSEED OIL NASAL AEROSOL, SPRAY 50.50 mg Deletion
138093 Q3 2022 CROSPOVIDONE ORAL TABLET, MULTILAYER, EXTENDED RELEASE 5.00 mg Deletion
138183 Q2 2022 CALCIUM ACETATE ORAL SYRUP 3.00 mg/ 5.00 ml MDE Replacement
138184 Q3 2022 CALCIUM ACETATE ORAL SYRUP 6mg MDE Replacement
138185 Q2 2022 CALCIUM STEARATE ORAL POWDER 30.00 mg MDE Replacement
138186 Q3 2022 CALCIUM STEARATE ORAL POWDER 600mg MDE Replacement
138187 Q2 2022 CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) ORAL CAPSULE 8.00 mg MDE Replacement
138188 Q3 2022 CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) ORAL CAPSULE 16mg MDE Replacement
138189 Q2 2022 CARBOXYMETHYLCELLULOSE CALCIUM ORAL TABLET 125.00 mg MDE Replacement
138190 Q3 2022 CARBOXYMETHYLCELLULOSE CALCIUM ORAL TABLET 505mg MDE Replacement
138191 Q2 2022 CARBOXYMETHYLCELLULOSE SODIUM ORAL PASTE 5.00 mg/ 1.00 ml MDE Replacement
138192 Q3 2022 CARBOXYMETHYLCELLULOSE SODIUM ORAL PASTE 150mg MDE Replacement
138193 Q2 2022 CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM ORAL SUSPENSION 1975 mg MDE Replacement
138194 Q3 2022 CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM ORAL SUSPENSION 71mg MDE Replacement
138195 Q2 2022 CHLOROBUTANOL NASAL SOLUTION 5.25 mg MDE Replacement
138196 Q3 2022 CHLOROBUTANOL NASAL SOLUTION 2mg MDE Replacement
138197 Q2 2022 CITRIC ACID MONOHYDRATE NASAL SPRAY, METERED 1.70 mg/ 1.00 ml MDE Replacement
138198 Q3 2022 CITRIC ACID MONOHYDRATE NASAL SPRAY, METERED 1mg MDE Replacement
138199 Q2 2022 CITRIC ACID MONOHYDRATE ORAL POWDER, FOR SOLUTION 315.00 mg MDE Replacement
138200 Q3 2022 CITRIC ACID MONOHYDRATE ORAL POWDER, FOR SOLUTION 315mg MDE Replacement
138201 Q2 2022 COMPRESSIBLE SUGAR ORAL POWDER, FOR SOLUTION 1851.94 mg/ 5.00 ml MDE Replacement
138202 Q3 2022 COMPRESSIBLE SUGAR ORAL POWDER, FOR SOLUTION 37039mg MDE Replacement
138203 Q2 2022 COTTONSEED OIL INTRAMUSCULAR INJECTION 87.46 %w/v MDE Replacement
138204 Q3 2022 COTTONSEED OIL INTRAMUSCULAR INJECTION 1084mg MDE Replacement
138205 Q2 2022 CROSCARMELLOSE SODIUM ORAL SUSPENSION 143.50 mg/ 5.00 ml MDE Replacement
138206 Q3 2022 CROSCARMELLOSE SODIUM ORAL SUSPENSION 150mg MDE Replacement
138207 Q2 2022 CROSPOVIDONE ORAL GRANULE, FOR SOLUTION 36.30 mg MDE Replacement
138208 Q3 2022 CROSPOVIDONE ORAL GRANULE, FOR SOLUTION 18mg MDE Replacement
138209 Q2 2022 CROSPOVIDONE ORAL GRANULE, FOR SUSPENSION 23.32 mg MDE Replacement
138210 Q3 2022 CROSPOVIDONE ORAL GRANULE, FOR SUSPENSION 47mg MDE Replacement
138211 Q2 2022 CYCLOMETHICONE 5 TOPICAL CREAM, AUGMENTED 13.00 %w/w MDE Replacement
138212 Q3 2022 CYCLOMETHICONE 5 TOPICAL CREAM, AUGMENTED 260mg MDE Replacement
138213 Q2 2022 CYSTEINE HYDROCHLORIDE INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 25.00 mg MDE Replacement
138214 Q3 2022 CYSTEINE HYDROCHLORIDE INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100mg MDE Replacement
138215 Q2 2022 CYSTEINE HYDROCHLORIDE INTRAVENOUS SOLUTION 0.03 %w/v MDE Replacement
138216 Q3 2022 CYSTEINE HYDROCHLORIDE INTRAVENOUS SOLUTION 100mg MDE Replacement

 

 

FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly

Data Through: July 1, 2022
Database Last Updated: July 18, 2022

Back to Top